Synektik S.A.

Książek Holding Initiates Sale of Synektik S.A. Shares Through Accelerated Bookbuilding Process

On June 16, 2026, Książek Holding Sp. z o.o., a major shareholder of Synektik S.A., announced the commencement of an accelerated bookbuilding process (ABB) to sell approximately 1,376,143 shares of Synektik S.A., representing 16.13% of the company's share capital and 16.3% of its total voting rights. The sale is directed exclusively at qualified investors and institutional investors meeting specific criteria, with no requirement for a prospectus or public offering documentation under EU regulations. The final sale price and the total number of shares sold will be determined after the bookbuilding process concludes. IPOPEMA Securities S.A. and UniCredit Bank GmbH, Milan Branch, will act as the sole global coordinators and bookrunners for the transaction. Książek Holding has also committed to a 180-day lock-up period for its remaining shares post-transaction, with certain exceptions.

The ABB process may be modified, suspended, or canceled at any time without prior notice. The sale is part of Książek Holding's strategic decision to divest its stake in Synektik S.A., which is a leading Polish medical technology company specializing in radiopharmaceutical production, medical equipment distribution, and IT solutions for healthcare.

Relevance to Synektik S.A.: This development is significant for Synektik S.A. as it involves a substantial change in the ownership structure, potentially impacting the company's strategic direction and market perception.

State-of-the-Art Robotic Surgery and Radiotherapy Infrastructure Introduced at Zamość Provincial Hospital

The Provincial Hospital in Zamość has joined over 100 hospitals in Poland utilizing robotic surgery systems by acquiring the advanced da Vinci Xi surgical robot. The system, purchased for over PLN 19 million through the National Recovery Plan (KPO), is being used for minimally invasive surgeries, particularly in urology and colorectal cancer treatments. Dr. Mirosław Kawałko, head of the urology department, highlighted the importance of robotic surgeries in modern medical treatment, especially for prostate cancer, as they combine the precision of open surgery with the minimally invasive benefits of laparoscopy. The hospital began performing robotic surgeries in May, with plans to expand their use further.

In addition to the robotic surgery system, the hospital has invested PLN 52 million (including PLN 48 million from KPO funds) to upgrade its radiotherapy infrastructure. This includes the replacement of two high-energy accelerators, a new CT scanner, and the implementation of advanced treatment planning systems. The new equipment features cutting-edge technologies such as Flattening Filter Free (FFF) technology, advanced dosimetry, and respiratory gating systems, which enhance treatment precision, reduce exposure to healthy tissues, and shorten therapy sessions. The hospital's collaboration with Affidea NU-MED has also created a comprehensive oncology diagnostic and treatment center, providing patients with a full range of services in one location.

According to Adam Fimiarz, director of the hospital, and Agnieszka Szydłowska, COO of Radiotherapy at Affidea Poland, these investments significantly improve the quality, accessibility, and safety of oncological care in the region, ensuring long-term benefits for patients.

Relevance to Synektik S.A.: The acquisition of the da Vinci Xi surgical robot highlights Synektik S.A.'s role as the exclusive distributor of Intuitive Surgical's robotic systems in Poland, showcasing the growing adoption of their cutting-edge medical technologies in the healthcare sector.

Synektik S.A. Reports Robust Financial Growth Amid Strategic Business Developments

Synektik S.A., a leading Polish medical technology company, has reported significant financial growth for the first half of FY2026, ending March 31, 2026. The company achieved consolidated revenues of PLN 441.16 million, marking a 34.5% increase compared to the same period in FY2025. Net profit surged to PLN 331.33 million, a remarkable 596.9% year-on-year growth, driven by the successful completion of the company's strategic division and the creation of Syn2bio S.A. This division resulted in a non-cash gain of PLN 261.32 million, reflecting the value of assets transferred to Syn2bio S.A., which focuses on innovative pharmaceutical research and development.

Synektik's core business segments—medical equipment and IT solutions, and radio pharmaceuticals—continued to perform strongly. The medical equipment segment contributed PLN 415.81 million to total revenues, while the radio pharmaceuticals segment added PLN 28.58 million. The company also reported a significant increase in EBITDA from continuing operations, reaching PLN 118.03 million, up from PLN 80.94 million in the previous year.

Despite the positive financial results, Synektik faced challenges in its operational cash flow, which decreased by PLN 48.12 million due to increased costs associated with scaling operations and higher working capital requirements. Additionally, the company highlighted the impact of geopolitical tensions, including the ongoing war in Ukraine and instability in the Middle East, on its financial and operational environment.

Synektik's strategic focus on expanding its portfolio, including advanced medical technologies like the da Vinci robotic surgical systems, and its commitment to innovation through its research centers, remain central to its growth trajectory.

Relevance to Synektik S.A. Company Profile

This article is highly relevant to Synektik S.A.'s business profile as it underscores the company's financial performance, strategic initiatives, and its role as a leader in medical technology and radio pharmaceuticals in Poland.

Synektik S.A. Expands Operations to Ukraine with Plans for 20 da Vinci Robotic Systems

Polish medical technology company Synektik S.A. has announced its entry into the Ukrainian market, marking a significant step in its international expansion strategy. Over the next two years, the company plans to install approximately 20 da Vinci robotic surgical systems in Ukraine, aiming to enhance the country's access to advanced minimally invasive surgical technologies. This move aligns with Synektik's commitment to providing cutting-edge medical solutions and expanding the adoption of robotic-assisted surgeries in new markets.

The da Vinci system, developed by Intuitive Surgical and exclusively distributed by Synektik in Poland, is renowned for its precision and versatility in various surgical specialties, including urology, gynecology, and cardiothoracic surgery. By introducing these systems to Ukraine, Synektik seeks to address the growing demand for innovative healthcare technologies in the region.

Relevance: This development underscores Synektik's strategic focus on expanding its footprint in the medical technology sector and promoting the adoption of robotic surgical systems, a key component of its business model.

Wojskowy Instytut Medyczny Becomes Central Europe's First da Vinci Robotic Surgery Reference Center

The Military Institute of Medicine (Wojskowy Instytut Medyczny, WIM) in Warsaw has been designated as the first reference center for da Vinci robotic surgery in Central Europe. This milestone follows an agreement between WIM and Intuitive, the manufacturer of the da Vinci surgical system, marking the first such partnership in Poland. As an official European case observation center, WIM will provide clinical training for medical professionals from Poland and abroad, enabling them to enhance their skills in robotic surgery.

The training program will include live observation of advanced procedures performed by experienced da Vinci surgeons, adhering to the highest clinical standards and ensuring patient safety and confidentiality. The program will be led by seasoned robotic surgeons from WIM, including Dr. Jacek Doniec, specializing in robotic gynecology, and Dr. Michał Wiłkojć, focusing on robotic thoracic surgery. Training will cater to all levels, from basic to advanced robotic surgery techniques.

Synektik S.A., the exclusive distributor of da Vinci systems in Poland, as well as in the Czech Republic, Slovakia, the Baltic states, and Ukraine, plays a pivotal role in this development. The company currently oversees approximately 140 da Vinci robots in the region. Cezary Kozanecki, founder and CEO of Synektik, emphasized the importance of this partnership, highlighting the growing demand for robotic surgery and the need for high-quality training centers. He also noted WIM's status as one of the most advanced robotic surgery centers in the region, performing procedures across all available specialties, making it an ideal partner for this international knowledge-sharing initiative.

Relevance to Synektik S.A.: This development underscores Synektik's leadership in the distribution and support of advanced medical technologies, particularly the da Vinci robotic surgery systems, while reinforcing its commitment to advancing medical education and innovation in Central and Eastern Europe.

Synektik S.A. Secures Key Contract with Szczecin Provincial Hospital for da Vinci Surgical System Supplies

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the Independent Public Provincial Integrated Hospital in Szczecin. The contract, valued at a maximum net amount of PLN 10,099,130.41, pertains to the supply of consumables for the da Vinci robotic surgical system used in minimally invasive procedures at the hospital. The agreement was finalized following a public procurement process conducted through an open tender and will span a period of 24 months.

The deal is considered crucial by Synektik's management, as its value exceeds 5% of the estimated equity of the Synektik Capital Group, meeting the company's internal reporting standards for significant transactions. Revenue generated from this project is expected to positively impact the company's sales performance during the fiscal years 2025-2027.

Relevance to Synektik S.A.: This agreement underscores Synektik's strategic focus on providing advanced medical technologies, including robotic surgical systems, and aligns with its position as the exclusive distributor of the da Vinci system in Poland.

Synektik S.A. Completes Strategic Spin-Off of Syn2Bio S.A., Reports Financial Impact

Synektik S.A., a leading Polish medical technology company, has finalized the spin-off of its business segment focused on the cardiomarker project and the Center for Research on New Molecules into Syn2Bio S.A. The transaction, executed as a non-cash dividend distribution to shareholders, resulted in a recognized profit of approximately PLN 261 million, calculated based on the fair value of Syn2Bio S.A. shares at their debut on the Warsaw Stock Exchange on April 16, 2026. This profit reflects the difference between the fair value of the shares and the net asset value of the transferred business segment, which amounted to approximately PLN 43 million.

As part of the spin-off, Synektik S.A.’s equity decreased by approximately PLN 304 million, recorded as "Capital from Spin-Off," leading to a net reduction in equity of around PLN 43 million. These figures will be finalized in the company’s interim financial statements for the period ending March 31, 2026, subject to auditor review.

The spin-off aligns with Synektik S.A.’s strategic focus on its core business areas, including the production of radiopharmaceuticals, distribution of advanced medical equipment, and development of IT solutions for healthcare.

Relevance: This development highlights Synektik S.A.’s strategic decision to streamline its operations and focus on its primary business segments, reinforcing its position as a leader in medical technology and innovation in Poland.

Polish Healthcare System Unprepared for Crisis Situations, Warns Medical Federation

The Federation of Zielona Góra Agreement (Porozumienie Zielonogórskie) has raised concerns about Poland's healthcare system's readiness to handle crisis situations. According to the Federation, the country lacks cohesive procedures, clear role definitions, and effective decision-making frameworks to ensure the continuity of primary healthcare services during emergencies such as energy outages, cyberattacks, natural disasters, epidemics, or logistical disruptions.

Experts emphasize that primary healthcare (POZ) is the cornerstone of the healthcare system, bearing the responsibility for managing chronic patients, seniors, and those requiring continuous care. Any disruption in POZ operations during a crisis could lead to system-wide overload and jeopardize access to essential services for millions of patients. The Federation has called for systemic reforms, including:

• Defining the role of primary healthcare in crisis scenarios,
• Establishing clear decision-making and communication structures,
• Developing procedures to ensure the continuity of medical services,
• Securing energy and digital infrastructure for healthcare,
• Clarifying the deployment of medical personnel during emergencies.

Marek Sobolewski, a family medicine specialist and expert from the Federation, highlighted the organizational challenges, noting that current plans often assign overlapping responsibilities to the same individuals, making them impractical in real-world scenarios. The Federation urges the government to collaborate with healthcare representatives to create a comprehensive crisis management model.

Relevance to Synektik S.A.: Synektik S.A.'s expertise in providing advanced medical technologies, IT solutions, and critical healthcare infrastructure positions the company as a key player in addressing the gaps in Poland's healthcare crisis preparedness. Their innovative solutions, such as imaging systems and IT platforms, could play a vital role in ensuring the resilience of healthcare services during emergencies.

Robotic Surgery Coordinators: A New Frontier in Polish Healthcare

As robotic surgical systems become increasingly prevalent in Polish hospitals, the role of robotic surgery coordinators is emerging as a critical yet undefined profession. Kaja Pulkowska, a robotic coordinator at the Center for Robotic Surgery in Bydgoszcz's Oncology Center, highlights the growing importance of this role in ensuring seamless operations and supporting medical teams. Coordinators are responsible for managing the integration of advanced robotic systems, such as the da Vinci Surgical System, into hospital workflows. Their duties include liaising with distributors like Synektik S.A., organizing training sessions for medical staff, and ensuring the readiness and maintenance of robotic systems for surgeries.

With nearly 100 robotic systems now operational in Poland, including three da Vinci systems at the Bydgoszcz center alone, robotic-assisted surgeries are becoming a preferred option for patients due to their precision and minimally invasive nature. Despite the increasing demand, the role of robotic coordinators remains unregulated, with no standardized qualifications or legal framework. Experts like Pulkowska advocate for formal recognition of the profession to ensure consistent standards and support for medical teams as robotic systems become a staple in operating rooms.

Relevance to Synektik S.A.: As the exclusive distributor of the da Vinci Surgical System in Poland, Synektik S.A. plays a pivotal role in the adoption and integration of robotic surgical technologies in the country. The article underscores the growing demand for robotic systems and highlights the importance of Synektik's role in providing equipment, training, and support to healthcare facilities. This aligns with the company's mission to advance medical technology and improve healthcare outcomes.

Synektik S.A. Secures Major Contract for da Vinci Surgical System in Czech Republic

Synektik S.A., through its subsidiary SYNEKTIK Czech Republic, s.r.o., has signed significant agreements with Oblastní nemocnice Příbram, a.s., a hospital based in Příbram, Czech Republic. The contracts encompass the sale, delivery, installation, and commissioning of the da Vinci robotic surgical system, along with staff training, warranty service, post-warranty service for three years, and the supply of consumables throughout the system's operational lifespan.

The agreements, concluded following a public procurement process under Czech law, are valued at a net total of €3,669,607. Delivery of the robotic system is expected within 10 weeks of the hospital's delivery request, with a warranty period of 60 months starting from the final acceptance protocol. The revenue generated from this project will contribute to Synektik's financial results from fiscal years 2025 to 2033.

The Synektik Management Board has classified these agreements as significant, as their total net value exceeds 5% of the Group's equity, as reported in its latest periodic financial statement.

Relevance: This development underscores Synektik S.A.'s leading position in the distribution and implementation of advanced medical technologies, particularly the da Vinci robotic surgical system, which aligns with its core business focus on medical equipment and healthcare IT solutions.